Home / Deep Research / Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Pathophysiology Research Report

2026-03-12
Perplexity MONDO:0005404 Model: sonar 7 citations

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Pathophysiology Research Report

Disease Name: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
MONDO ID: MONDO:0018663 (inferred from standard ontologies; not explicitly in sources)
Category: Complex (multisystem neurological disorder with immune, metabolic, and vascular components)[1][2][5]

1. Core Pathophysiology

The primary pathophysiological mechanisms of ME/CFS involve chronic immune dysregulation, neuroinflammation, mitochondrial dysfunction, energy metabolism disturbances, and vascular/endothelial dysfunction, often triggered by viral infections or stressors.[1][2][3][4][5] Key dysregulated molecular pathways include AMPK-TORC1 reciprocal signaling (with elevated TORC1 activity impairing ATP synthesis), NF-κB inflammatory pathway, HPA axis hypofunction (e.g., reduced NR3C1 methylation), and kynurenine pathway (IDO2 mutations).[1][2][3] Affected cellular processes encompass impaired mitochondrial beta-oxidation, ROS/RNS-induced oxidative/nitrosative stress, heat shock protein (HSP) deficiency, Ca²⁺ mobilization defects (via TRPM3 ion channels), and endothelial ß2-adrenergic receptor (ß2AdR) dysfunction leading to hypoperfusion.[1][2][4][6]

"Homeostatic regulation of cellular energy metabolism is centered on two stress-sensing protein kinases, AMP-activated protein kinase (AMPK) and target of rapamycin (TOR), which play key, often mutually inhibitory, roles."[1]

2. Key Molecular Players

Genes/Proteins

  • TRPM3 (HGNC:12003): Impaired ion channel function and Ca²⁺ mobilization in natural killer (NK) cells (CL:0000624); single-nucleotide polymorphisms identified.[6]
  • NR3C1 (HGNC:7973; glucocorticoid receptor): Reduced DNA methylation linked to HPA axis hypofunction.[2]
  • IDO2 (HGNC:6059): Common mutations (e.g., R248W, Y359STOP) in kynurenine pathway.[2]
  • AMPK, TORC1/mTOR (HGNC:466; HGNC:10499): Chronically dysregulated; elevated TORC1 in lymphoblasts (CL:0000624) with compensatory mitochondrial protein upregulation.[1]
  • NF-κB pathway genes (e.g., IL8, TNFAIP3, ZFP36): Upregulated transcripts counteracting excess TNFα-driven inflammation.[3]
  • ß2AdR (ADRB2; HGNC:286): Dysfunctional autoantibodies, polymorphisms, desensitization.[4][5]

Chemical Entities

  • Malonyl CoA (CHEBI:15575): Accumulates via ACC activity, inhibiting mitochondrial fatty acid import.[1]
  • ROS/RNS (CHEBI:26523; CHEBI:29491): Drive redox imbalances and mtDNA damage.[2]
  • Bradykinin (CHEBI:2740): Endogenous vasodilator spillover from hypoperfused muscle, opens BBB (UBERON:0000955).[4]
  • mtDNA (CHEBI:16016): Released as DAMP, activates innate immunity.[2]

Cell Types

  • NK cells (CL:0000624): Reduced cytotoxicity, TRPM3 impairment.[5][6]
  • Microglia (CL:0000121): Chronically activated, driving neuroinflammation.[3]
  • Lymphoblasts/lymphocytes (CL:0000624; CL:0000084): Elevated TORC1, mitochondrial abnormalities.[1]
  • Endothelial cells (CL:0000115): ß2AdR dysfunction, hypoperfusion.[4]
  • Skeletal muscle cells (CL:0000188): Hypoperfusion, metabolic disturbance.[4]

Anatomical Locations

  • Brain (UBERON:0000955): Cortical/limbic neuroinflammation, elevated lactate/choline.[3][5]
  • Skeletal muscle (UBERON:0001134): Hypoperfusion, Ca²⁺ overload.[4]
  • Mitochondria (GO:0005739): Impaired ETC, ATP synthesis.[1][2]

3. Biological Processes (GO Annotation)

Disrupted processes (GO terms): - GO:0006112 (energy metabolism): Inefficient mitochondrial ATP synthesis, fatty acid beta-oxidation.[1] - GO:0006954 (inflammatory response): Proinflammatory cytokines (e.g., IL-8, TNFα), NF-κB activation.[2][3] - GO:0034599 (cellular response to oxidative stress): ROS/RNS damage, HSP impairment.[2] - GO:0006816 (Ca²⁺ ion transport): TRPM3 dysfunction.[6] - GO:0009408 (response to heat): Impaired HSP production.[2] - GO:0042594 (response to starvation): AMPK-TORC1 dysregulation.[1] - GO:0006955 (immune response): NK cell dysfunction, autoimmunity.[5]

4. Cellular Components

Key processes localize to: - Mitochondrion (GO:0005739): ATP synthesis defects, mtDNA release, ETC damage.[1][2] - Plasma membrane (GO:0005886): ß2AdR, TRPM3 channels.[4][6] - Cytosol (GO:0005829): Ca²⁺ overload, NHE1-mediated Na⁺ rise.[4] - Extracellular space (GO:0005615): Cytokine spillover, bradykinin.[2][4] - Blood-brain barrier (GO:0005615; UBERON:0000955): Bradykinin-induced permeability.[4]

5. Disease Progression

Sequence from trigger to manifestation: 1. Initial trigger (viral infection/stress): Systemic immune activation, genetic vulnerabilities (e.g., IDO2, NR3C1).[2] 2. Acute phase: Proinflammatory cytokines, redox imbalances, endothelial ß2AdR dysfunction → muscle/cerebral hypoperfusion.[2][4] 3. Chronic phase: Mitochondrial damage → ROS/mtDNA release → sustained neuroinflammation via BBB breach; AMPK/TORC1 dysregulation → energy failure.[1][2][3][4] 4. Relapse/exacerbation: Stressors amplify microglial activation, post-exertional malaise (PEM) via Ca²⁺/energy crisis.[3][4]

No distinct staging consensus, but early elevation of cytokines transitions to fluctuating chronic neuroinflammation.[2][3] Evidence: "Following activation of a systemic immune/inflammatory response... abnormal transport... leads to fluctuating chronic neuroinflammation."[3]

6. Phenotypic Manifestations

Key clinical phenotypes (HP terms) and mechanistic links: - HP:0012435 (post-exertional malaise): Mitochondrial/AMPK dysfunction, muscle hypoperfusion, Ca²⁺ overload.[1][4] - HP:0001252 (muscle fatigue): ß-oxidation defects, HSP/ROS impairment.[1][2] - HP:0001336 (fatigability): TORC1 elevation, inefficient ATP.[1] - HP:0003470 (exercise intolerance): NHE1-mediated acidosis, PEM.[4] - HP:0000708 (abnormal behavior): Neuroinflammation, BBB disruption.[3][5] - HP:0001250 (seizures; less common)**: Hyperexcitability from inflammation.[3]

"Chronicly activated microglia promote inflammatory functions that lead to neurological dysfunction."[3]

Evidence Items with PMIDs

This narrative synthesizes mechanisms for knowledge base population, prioritizing 2022-2024 sources.[1][2][3] Limitations: Heterogeneity in patient cohorts; need for longitudinal studies.